Targeting Drug resistant mutations using novel binding interactions - lessons learned from Abl-T315I and their implications in Drug design

Frontiers in Drug Design and Discovery

Volumn 3, Issue 1, 2007, Pages 121-144

  Noronha, Glenn ^a   Cao, Jianguo ^a   Chow, Chun ^a   Dneprovskaia, Elena ^a   Hwang, Linda ^a   Lohse, Dan ^a   Mak, Chi Ching ^a   McPherson, Andrew ^a   Fine, Richard M ^b   Kang, Xinshan ^b   Klebansky, Boris ^b   Palanki, Moorthy S S ^a   Pathak, Ved P ^a   Renick, Joel ^a   Soll, Richard ^a   Zeng, Binqi ^a  

^a TargeGen Inc   (United States)

^b BioPredict Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47249153958     PISSN: 15740889     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (58)

1. Williams, J. C.; Weijland, A.; Gonfloni, S.; Thompson, A.; Courtneidge, S. A.; Superti-Furga, G.; Wierenga, R. K. J. Mol. Biol., 1997, 274, 757.
2. Xu, W.; Harrison, S. C.; Eck, M. J. Nature, 1997, 385, 595.
3. Superti-Furga, G.; Courtneidge, S. A. Bioessays, 1995, 17, 321.
4. Sicheri, F.; Moarefi, I.; Kuriyan, J. Nature, 1997, 385, 602.
5. Trevino, J. G.; Summy, J. M.; Gallick, G. E. Mini Rev. Med. Chem., 2006, 6, 681.
6. Lowell, C. A.; Soriano, P. Genes Dev., 1996, 10, 1845.
7. Brown, M. T.; Cooper, J. A. Biochem. Biophys. Acta, 1996, 1287, 121.
8. Weis, S.; Shintani, S.; Weber, A.; Kirchmair, R.; Wood, M.; Cravens, A.; McSharry, H.; Iwakura, A.; Yoon, Y; Himes, N.; Burstein, D.; Doukas, J; Soll, R.; Losordo, D.; Cheresh, D. J. Clin. Invest., 2004, 113, 885.
9. Paul, R.; Zhang, Z. G.; Eliceiri, B. P.; Jiang, Q.; Boccia, A. D.; Zhang, R. L.; Chopp, M.; Cheresh, D. A. Nat. Med., 2001, 7, 222.
10. Susva, M.; Missbach, M.; Green, J. Trends Pharmacol. Sci., 2000, 21, 489.
11. Yeatman, T. J. Nat. Rev. Cancer, 2004, 4, 470.
12. Talamonti, M. S.; Roh, M. S.; Curley, S. A.; Gallick, G. E. J. Clin. Invest., 1993, 91, 53.
13. Wiener, J. R.; Windham, T. C.; Estrella, V. C.; Parikh, N. U.; Thall, P. F.; Deavers, M. T.; Bast, R. C.; Mills, G. B.; Gallick, G. E. Gynecol. Oncol., 2003, 88, 73.
14. Ito, H.; Gardner-Thorpe, J.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. Surgery, 2003, 134, 221.
15. Summay, J. M.; Gallick, G. E. Cancer Metastasis Rev., 2003, 22, 337.
16. Irby, R. B.; Yeatman, T. J. Oncogene, 2000, 19, 5636.
17. Kanerva, J.; Nwawka, O.; Hwang1, K.; Lee, F. Y.; Corey, S. J. Blood, 2004, 104, Abstract 4480.
18. Boschelli, D. H.; Wu, B.; Sosa, A. C. B.; Durutlic, H.; Ye, F.; Raifeld, Y.; Golas, J. M.; Boschelli, F. J. Med. Chem., 2004, 47, 6666.
19. Boschelli, D. H.; Wu, B.; Sosa, A. C. B.; Durutlic, H.; Chen, J. J.; Wang, Y. Golas, J. M.; Lucas, J.; Boschelli, F. J. Med. Chem., 2005, 48, 3891.
20. Boschelli, D. H.; Wu, B.; Sosa, A. C. B.; Chen, J. J.; Golas, J. M.; Boschelli, F. Bioorg. Med. Chem. Lett., 2005, 15, 4681.
21. Manetti, F.; Locatelli, G. A.; Maga, G.; Schenone, S.; Modugno, M.; Forli, S.; Corelli, F.; Botta, M. J. Med. Chem., 2006, 49, 3278.
22. Carraro, F.; Naldini, A.; Pucci, A.; Locatelli, G. A.; Maga, G.; Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Brullo, C.; Fossa, P.; Menozzi, G.; Mosti, L.; Modugno, M.; Tintori, C.; Manetti, F.; Botta, M. J. Med. Chem., 2006, 49, 1549.
23. Dalgarno, D.; Stehle, T.; Narula, S.; Schelling, P.; van Schravendijk, M.; Adams, S.; Andrade, L.; Keats, J.; Ram, M.; Jin, L.; Grossman, T.; MacNeil, I.; Metcalf, C.; Shakespeare, W.; Wang, Y.; Keenan, T.; Sundaramoorthi, R.; Bohacek, R.; Weigele, M.; Sawyer, T. Chem. Biol. Drug Des., 2006, 67, 46.
24. Wang, Y.; Metcalf, C.; Shakespeare, W.; Sundaramoorthi, R.; Keenan, T.; Bohacek, R.; Van Schravendijk, M.; Violette, S.; Narula, S.; Dalgarno, D.; Haraldson, C.; Keats, J.; Liou, S.; Mani, U.; Pradeepan, S.; Ram, M.; Adams, S.; Weigele, M.; Sawyer, T. Bioorg. Med. Chem. Lett., 2003, 13, 3067.
25. Honold, K.; Kaluza, K.; Masjost, B.; Schaefer, W.; Scheiblich, S. Hoffmann-La Roche, WO2006066913, 2006.
26. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. Mol. Cell, 1999, 3, 639.
27. Xu, W.; Doshi, A.; Lei, M.; Eck, M. J.; Harrison, S. C. Mol. Cell, 1999, 3, 629.
28. Cowan-Jacob, S. W.; Fendrich, G.; Manley, P. W.; Jahnke, W.; Fabbro, D.; Liebetanz, J.; Meyer, T. Structure, 2005, 13, 861.
29. Hunter, T. Cell, 1987, 49, 1.
30. Superti-Furga, G.; Courtneidge, S. A. Bioessays, 1995, 17, 321.
31. Matsuda, M.; Mayer, B. J.; Fukui, Y.; Hanafusa, H. Science, 1990, 248, 1537.
32. The fully activated catalytic domain of human Src kinase was built based on available crystal structures of activated Lck. The model was built using the interactive programs InsightII and Homology from Accelrys. Ligands were docked initially into the active site using an automated modeling program BioDock (NIH SBIR Grant 1R43GM071055) and subsequently using interactive modeling in InsightII. Models with and without ligands were subjected to energetic refinement including solvent using the Accelerys program Discover. Visualization was generated using the program BioInterpreter (NIH SBIR Grant 5R44GM061465).
33. http://www.pdb.org/
34. Klutchko, S. R.; Hamby, J.M.; Boschelli, D.H.; Wu, Z.; Kraker, A.J.; Amar, A.M.; Hartl, B.G.; Shen, C.; Klohs, W.D.; Steinkampf, R.W.; Driscoll, D.L.; Nelson, J.M.; Elliott, W.L.; Roberts, B.J.; Stoner, C.L.; Vincent, P.W.; Dykes, D.J.; Panek, R.L.; Lu, G.H.; Major, T.C.; Dahring, T.K.; Hallak, H.; Bradford, L.A.; Showalter, H.; Doherty, A. J. Med. Chem., 1998, 41, 3276.
35. Xu, W.; Harrison, S. C.; Eck, M. J. Nature, 1997, 385, 595.
36. Palanki, M. S. S.; Cao, J.; Chow, C. P.; Dneprovskaia, E.; Fine, R.; Gritzen, C.; Kang, X.; Klebansky, B.; Mak, C. C.; McPherson, A.; Noronha, G.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. Poster #7, 8th Winter Conference of Medicinal and Bioorganic Chemistry, Steamboat Springs, Colorado, January 21-25, 2007.
37. Noronha, G.; Barrett, K.; Cao, J.; Dneprovskaia, E.; Fine, R.; Gong, X.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Wrasidlo, W.; Zeng, B.; Zhao, N. Bioorg. Med. Chem. Lett., 2006, 16, 5546.
38. It is worth commenting that of the three potential hydrogen bond interactions to the backbone of the hinge the ligand acceptor interaction is crucial in that it is exhibited by virtually all co-crystals of ATP-competitive kinase inhibitors. The other two ligand-donor interactions are less crucial, seemingly contributing only added affinity and helping to select ligand orientation on binding.
39. Noronha, G.; Barrett, K.; Boccia, A.; Brodhag, T.; Cao, J.; Chow, C. P.; Dneprovskaia, E.; Doukas, J.; Fine, R.; Gong, X.; Gritzen, C.; Gu, H.; Hanna, E.; Hood, J. D.; Hu, S.; Kang, X.; Key, J.; Klebansky, B.; Kousba, A.; Li, G.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Shi, F.; Soll, R.; Splittgerber, U.; Stoughton, S.; Tang, S.; Yee, S.; Zeng, B.; Zhaoa, N.; Zhu H. Bioorg. Med. Chem. Lett., 2007, 17, 602.
40. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J.C.; Behnia, K.; Castaneda, S.; Cornelius, A.M.; Das, J.; Doweyko, A.M.; Fairchild, C.; Hunt, J.T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G.L.; Schmidt, R.J.; Tokarski, J.; Wen, M.; Wityak, J.; Borzilleri, R.M. J. Med. Chem., 2004, 47, 6658.
41. Martin, M. W.; Newcomb, J.; Nunes, J. J.; McGowan, D. C.; Armistead, D. M.; Boucher, C.; Buchanan, J. L.; Buckner, W.; Chai, L.; Elbaum, D.; Epstein, L. F.; Faust, T.; Flynn, S.; Gallant, P.; Gore, A.; Gu, Y.; Hsieh, F.; Huang, X.; Lee, J. H.; Metz, D.; Middleton, S.; Mohn, D.; Morgenstern, K.; Morrison, M. J.; Novak, P. M.; Oliveira-do-Santos, A.; Powers, D.; Rose, P.; Schneider, S.; Sell, S.; Tudor, Y.; Turci, S. M.; Welcher, A. A.; White, R. D.; Zack, D.; Zhao, H.; Zhu, L.; Zhu, X.; Ghiron, C.; Amouzegh, P.; Ermann, M.; Jenkins, J.; Johnston, D.; Napier, S.; Power, E. J. Med. Chem., 2006, 49, 4981.
42. Snow, R. J.; Cardozo, M. G.; Morwick, T. M.; Busacca, C. A.; Dong, Y.; Eckner, R. J.; Jacober, S.; Jakes, S.; Kapadia, S.; Lukas, S.; Panzenbeck, M.; Peet, G. W.; Peterson, J. D.; Prokopowicz, A. S., III; Sellati, R.; Tolbert, R. M.; Tschantz, M. A.; Moss, N. J. Med. Chem., 2002, 45, 3394.
43. The X-ray crystal structure of active Src was solved. The results will be published soon.
44. Sawyers, C. L. N. Engl. J. Med., 1999, 340, 1330.
45. Pendergast, A. M.; Gishizky, M. L.; Havlik, M. H.; Witte, O. N. Mol. Cell. Biol., 1993, 13, 1728.
46. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Science, 2000, 289, 1938.
47. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M.; Paquette, R.L.; Kuriyan, J.; Sawyers, C. L. Cancer Cell, 2002, 2, 117.
48. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Chirchir, A. B.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. N. Engl. J. Med., 2006, 354, 2531.
49. Tokarski, J.S.; Newitt, J.A.; Chang, C. Y.; Cheng, J.D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y. F.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. Cancer Res., 2006, 66, 5790.
50. Willis, S.G.; Lange T.; Demehri, S.; Otto, S.; Crossman, L.; Niederwieser, D.; Stoffregen, E. P.; McWeeney, S.; Kovacs, I.; Park, B.; Druker, B. J.; Deininger. Blood, 2005, 106, 2128.
51. Nagar, B.; Hantschel, O.; Young, M. A.; Scheffzek, K.; Veach, D.; Bornmann, W.; Clarkson, B.; Superti-Furga, G.; Kuriyan, J. Cell, 2003, 112, 859.
52. Hantschel, O.; Nagar, B.; Guettler, S.; Kretzschmar, J.; Dorey, K.; Kuriyan, J.; Superti-Furga, G. Cell, 2003, 112, 845.
53. Harrison, S. C. Cell, 2003, 112, 737.
54. Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf III C.; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D. R.; Bornmann, W. G.; Clarkson, B.; Dalgarno, D.C.; Sawyer, T. K.; Daley, G. Q. Proc. Natl. Acad. Sci., 2006, 103, 9244.
55. Ki values for compounds were determined against Abl (Invitrogen) and the T315I mutant form of Abl (Upstate Cell Signaling Solutions). In white, flat-bottom, 96-well plates (Nunc) assays were run at room temperature at a final volume of 50 μL. Each well contained 40 μL of buffer consisting of 75 mM Tris buffer, pH 7.2 containing 95 mM MgCl2, 1.5 mM EGTA, 0.35 mM Triton X-100, 10 μM β- mercaptoethanol and an appropriate amount of either Abl or T315I-Abl such that the assay was linear over 60 min.
56. Unpublished results from TargeGen, Inc.
57. Cao, J.; Barrett, K.; Fine, R. M.; Gritzen, C.; Hood, J.; Kang, J.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Zeng, B.; Zhu, H. Abstracts of Papers, Abstract No. 251, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006.
58. Mak, C. C.; Barrett, K.; Cao, J.; Gritzen, C.; Hood, J.; McPherson, A.; Noronha, G.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Zeng, B. Abstracts of Papers, Abstract No. 65, 231st ACS National Meeting, Atlanta, GA, USA, March 26-30, 2006.